



Charles Erlichman, MD, FRCPC, FACP
 Co-Director for Experimental Therapeutics Committee
 Mayo Clinic
 200 First Street SW
 Rochester, MN 55905
 Phone: 507-266-3200
 Email: Erlichman.charles@mayo.edu

Gary Schwartz, MD
 Co-Director for Experimental Therapeutics Committee
 Columbia University
 177 Ft. Washington Avenue, Suite 6-435
 New York, NY 10032
 Phone: 212-305-2055
 Email: schwartzg@columbia.edu

Date: April 21, 2014
To: Experimental Therapeutics Committee
From: Charles Erlichman, MD and Gary Schwartz, MD
Re: **Experimental Therapeutics Committee Meeting**
Saturday, May 10, 2014
Time: **8AM-11AM Central**
Location: InterContinental Chicago O'Hare – Open Meeting Space – Metropolitan Room

Call In Information: 800-501-8979 / 8087368

AGENDA

1. Status update on activated current trials: *Horvath*

a.	A091104 (permanently closed to enrollment)	Phase II MK-2206 in Patients with progressive recurrent/metastatic Adenoid Cystic Carcinoma	A. Ho
b.	A091103 (permanently closed to accrual)	Phase 2 Study of Angiopoietin -1 and -2 peptibody AMG386 for the Treatment of Angiosarcoma	S. D'Angelo
c.	A091102 (suspended to accrual)	Phase II study of MLN8237 in advanced metastatic Sarcoma	M. Dickson
d.	A091101 (suspended to accrual)	TPF Induction chemotherapy and ABT-888- Phase 1/randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck	J. de Souza
e.	N1153 (suspended to accrual)	Phase I/II Study of Sorafenib + TH-302 in 1st line Advanced Hepatocellular Carcinoma (HCC) and 2nd line Renal Cell Carcinoma (RCC)	M. Borad
f.	N0871 (permanently closed to enrollment)	A Phase II Study of Carboplatin, Paclitaxel, and RAD001 in previously untreated Patients with Measurable Disease with Cancer of Unknown Primary (CUP)	M. Goetz
g.	N0879	A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma	R. McWilliams

h.	A091201	Randomized Phase II study comparing the MET Inhibitor XL184 to DTIC in Uveal Melanoma	J. Luke
i.	A091105	Phase 3 double blind randomized placebo controlled trial of Sorafenib in Desmoid Tumors	M. Gounder

2. Status update on current trials in development: *Schwartz or Horvath*

a.	A091302	Randomized Phase II study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer	E. Sherman
b.	A091305	A Phase 2 Double-Blind Randomized Study of Efatutazone, an Oral PPAR Agonist, in Combination with Paclitaxel versus Paclitaxel Plus Placebo in Patients with Advanced Anaplastic Thyroid Cancer	R. Smallridge
c.	A091202	A Phase II Randomized Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, CS-7017 (Efatutazone) vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma	M. Pishvaian

3. Status of Concepts: *Erlichman*

a.		Randomized Phase 2 study of chemo and androgen ablation in salivary gland cancer EORTC 1206/A091306 – <i>submitted to CTEP and BIQSFP for funding</i>	A. Ho
b.	A091304	A Randomized Phase II Study of MLN-0128 vs. Pazopanib in Patients with Advanced Sarcoma	W. Tap
c.	A091403-	Phase Ib/II Study of anti PD-1 Antibody MK-3475 In Combination With Ziv-aflibercept For The Treatment Of Metastatic Melanoma	A. Dudek
d.	A091401-	A Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma	S. D'Angelo
e.	A091402-	Phase I/II Study of combination BRAFV600, MEK1/2 and Heat Shock Protein 90 Inhibition by Vemurafenib, Cobimetinib and Ganetespib in BRAFV600 mutant melanoma	J. Luke

4. Update on NCI sponsored Match - *Schwartz*

5. Biomarker driven sarcoma trial proposal - *Horvath*

6. Health Outcomes Committee Update - *Ristvedt*

7. Central Office Updates - *Horvath*

- Personnel Changes: retirement of Linda Bressler (Elise Horvath is replacing her role), addition of Yujia Wen as Director of TRP, addition of Frazer Symmons as TRP PI
- Changes in Accrual Task Force
- Changes in SCRC
- NCTN Transition 3/1/14 and resultant changes